Sanofi-a Ventis Deutschland Gmbh

Sanofi

Heinz Goegelein

Klaus Wirth

Werngard Czechtizky

Olaf Ritzeler

John Weston

Volker Kraft

Nils Rackelmann

Petra Arndt

Joachim Brendel

Heinrich Christian Englert

Uwe Gerlach

Holger Heitsch

Stephanie Hachtel

Gary Mccort

Stefania Pfeiffer-Marek

Patrice Bellevergue

Michael Podeschwa

Maurits Allessie

Karl-Heinz Lehr

Yuri Blaauw

Yuri Department Of Physiology Blaauw

Maurits Department Of Physiology Allessie

The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them. 

Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals

The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals

The present invention relates to piperidinesulfonylureas and piperidinesulfonylthioureas of formula I, in which A, X, R(1), R(2) and R(3) have the meanings indicated in the claims. The compounds of formula I are valuable active pharmaceutical ingredients which show in particular an inhibiting effect on ATP-sensitive potassium channels of the cardiac muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as coronary heart disease, arrhythmias, cardiac insufficiency, cardiomyopathies or reduced contractility of the heart or for the prevention of sudden cardiac death. The invention further relates to processes for preparing the compounds of formula I, their use and pharmaceutical compositions comprising them.

Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them

The invention relates to the combination of one or more IKchannel blockers and of one or more Kv1.5 blockers, in particular phenyl-carboxamides of the formula Ia or Ib or pharmaceutically tolerable salts thereof, and the use of the combination for the treatment of atrial arrhythmias.

Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias

Growing community of inventors

Frankfurt am Main, Germany

Heinz Goegelein